| AFCLX | CEUAX | AFCLX / CEUAX | |
| Total Expense Ratio | 1.34 | 0.85 | 158% |
| Annual Report Gross Expense Ratio | 1.34 | 0.85 | 158% |
| Fund Existence | 10 years | 24 years | - |
| Gain YTD | 16.399 | 24.749 | 66% |
| Front Load | 6% | 4% | 164% |
| Min. Initial Investment | 2500 | 250 | 1,000% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 158M | 138B | 0% |
| Annual Yield % from dividends | 0.00 | 0.63 | - |
| Returns for 1 year | 13.25 | 17.15 | 77% |
| Returns for 3 years | 29.07 | 38.35 | 76% |
| Returns for 5 years | 5.53 | 11.60 | 48% |
| Returns for 10 years | N/A | 58.64 | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| AEIMX | 9.09 | 0.04 | +0.44% |
| American Century Equity Income G | |||
| BILSX | 10.42 | 0.04 | +0.39% |
| BlackRock U.S. Insights Lon/Shr Eq Ins | |||
| LEAOX | 15.87 | 0.04 | +0.25% |
| Lazard Emerging Markets Eq Advtg Open | |||
| ESMCX | 15.49 | 0.02 | +0.13% |
| Invesco Global Small Cap Equity C | |||
| FBTCX | 28.38 | N/A | N/A |
| Fidelity Advisor Biotechnology C | |||